Gufic Biosciences

₹323.5 4.4 | 1.4%

WEBSITE BSE:509079 NSE : GUFIC BIO SC 10 May, 16:01

Market Cap ₹3243 Cr.

Stock P/E 37.6

P/B 6.3

Current Price ₹323.5

Book Value ₹ 51.1

Face Value 1

52W High ₹364

Dividend Yield 0.03%

52W Low ₹ 193.6

Edit Ratio

Gufic Biosciences Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Gufic Biosciences Ltd is engaged within the manufacture of pharmaceuticals, medicinal chemicals and botanical merchandise. The Company's segments consist of Pharma, together with Formulations and Bulk Drugs, and Consumer. It has pharmaceutical products under categories, along with Criti Care, consisting of Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, which include Ticofic-200 and Gufivan-500; Ferticare, which include Puregraf 75IU 3-d, Cetrocare 0.25mg 3-D and Follicare 150IU 3D; Spark, inclusive of Aznee Duo, Eclin, Flabone, Vipro Fe, Vipro M and Zad G, and Herbal, such as Bocomo-Forte, River-Suspension, Sallaki-Liniment, Sallaki-Plus, Sallaki-XT and Smashit. Its personal care products consist of StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products below API/bulk tablets consist of Micafungin, Anidulafungin, Sulconazole, Everolimus and Butoconazole. It manufactures APIs underneath therapeutic classes, consisting of Antifungals and Immuno Suppressants.

Gufic Biosciences Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Gufic Biosciences Quarterly Results

#(Fig in Cr.)	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023
Net Sales	132	251	194	172	162	165	175	177	173	195
Other Income	1	1	0	2	0	0	1	1	1	1
Total Income	133	252	194	174	162	166	176	178	174	196
Total Expenditure	108	205	158	139	130	132	142	144	141	160
Operating Profit	24	47	36	34	33	34	33	34	33	36
Interest	3	1	2	1	1	1	2	2	3	4
Depreciation	4	4	4	4	5	4	5	5	6	4
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	17	42	30	29	26	28	27	27	24	28
Provision for Tax	4	10	7	8	6	7	7	7	6	7
Profit After Tax	13	31	23	21	20	21	20	20	18	21
Adjustments	-0	0	0	-0	-0	0	0	0	0	-0
Profit After Adjustments	13	31	23	21	20	21	20	20	18	21
Adjusted Earnings Per Share	1.3	3.2	2.4	2.2	2.1	2.2	2.1	2.1	1.9	2.1

Gufic Biosciences Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	100	123	152	202	246	306	351	379	488	779	691	720
Other Income	0	1	1	1	1	3	4	6	4	3	3	4
Total Income	101	124	152	203	247	308	355	385	491	782	693	724
Total Expenditure	89	111	137	183	223	267	305	327	404	631	556	587
Operating Profit	11	13	15	20	24	42	50	58	88	151	137	136
Interest	4	4	4	6	6	9	10	14	14	5	8	11
Depreciation	2	2	4	4	4	4	5	14	16	19	22	20
Exceptional Income / Expenses	0	0	0	0	0	2	0	0	0	0	0	0
Profit Before Tax	5	6	7	10	14	30	35	30	58	127	107	106
Provision for Tax	2	2	2	3	5	13	13	7	13	31	27	27
Profit After Tax	3	4	4	7	9	16	22	23	44	96	80	79
Adjustments	0	0	0	0	-0	-0	0	0	0	0	0	0
Profit After Adjustments	3	4	4	7	9	16	22	23	44	96	80	79
Adjusted Earnings Per Share	0.4	0.6	0.5	0.9	1.2	2.1	2.8	2.3	4.6	9.9	8.2	8.2

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-11%	22%	18%	21%
Operating Profit CAGR	-9%	33%	27%	29%
PAT CAGR	-17%	52%	38%	39%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	54%	23%	32%	49%
ROE Average	26%	33%	31%	26%
ROCE Average	23%	34%	30%	26%

Gufic Biosciences Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	22	26	27	34	37	54	75	129	173	269	348
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	18	15	12	8	7	8	11	20	35	48	191
Other Non-Current Liabilities	5	10	5	7	3	4	6	18	20	18	33
Total Current Liabilities	46	60	84	104	128	169	218	240	191	186	288
Total Liabilities	92	111	127	152	175	235	310	407	419	521	860
Fixed Assets	27	30	25	22	22	23	24	83	100	115	160
Other Non-Current Assets	13	12	11	11	9	14	22	51	32	85	237
Total Current Assets	52	69	91	120	143	198	264	273	288	321	464
Total Assets	92	111	127	152	175	235	310	407	419	521	860

Gufic Biosciences Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	1	1	3	6	4	3	4	4	4	6	12
Cash Flow from Operating Activities	5	11	11	-4	-4	-5	5	47	87	106	-27
Cash Flow from Investing Activities	-13	-3	-2	-1	-5	-9	-13	-43	-7	-95	-191
Cash Flow from Financing Activities	8	-7	-5	5	7	14	8	-4	-79	-6	234
Net Cash Inflow / Outflow	0	1	4	-0	-1	1	-0	0	2	5	17
Closing Cash & Cash Equivalent	1	3	6	6	3	4	4	4	6	12	29

Gufic Biosciences Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	0.43	0.55	0.54	0.95	1.17	2.12	2.82	2.34	4.56	9.89	8.22
CEPS(Rs)	0.71	0.87	1.04	1.44	1.64	2.68	3.42	3.77	6.24	11.84	10.52
DPS(Rs)	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.1	0.1	0.1
Book NAV/Share(Rs)	2.9	3.39	3.5	4.39	4.83	6.96	9.68	13.34	17.89	27.76	35.88
Core EBITDA Margin(%)	10.17	9.24	8.92	9.19	8.81	12.21	12.76	13.31	16.18	17.45	16.81
EBIT Margin(%)	8.47	7.82	6.87	7.73	7.95	12.23	12.63	11.25	13.75	15.59	14.35
Pre Tax Margin(%)	4.98	4.82	4.08	4.84	5.52	9.43	9.81	7.7	11.13	14.96	13.33
PAT Margin (%)	3.15	3.27	2.6	3.42	3.46	5.19	6.09	5.8	8.53	11.3	9.95
Cash Profit Margin (%)	5.21	5.17	5.01	5.19	4.88	6.57	7.38	9.34	11.67	13.53	12.74
ROA(%)	3.98	4.2	3.49	5.24	5.52	8.04	8.04	6.33	10.71	20.37	11.54
ROE(%)	15.89	17.55	15.6	23.99	25.31	36.03	33.89	22.17	29.22	43.31	25.84
ROCE(%)	18.44	17.45	18.38	24.24	24.26	34.1	29.65	21.01	30.05	47.29	23.23
Receivable days	73.52	67.55	70.29	76.38	75.93	76.39	93.16	97.98	81.43	59.4	81.36
Inventory Days	63.71	64.6	71.8	74.21	79.39	90.36	95.44	101.05	76.3	45.18	68.14
Payable days	167.83	170.43	202.01	205.22	163.71	169.93	173.92	227.3	184.25	124.89	167.52
PER(x)	14.8	9.32	24.04	44.25	56.89	51.14	26.98	20.15	25.05	25.18	22.7
Price/Book(x)	2.2	1.52	3.69	9.54	13.75	15.56	7.86	3.53	6.39	8.97	5.2
Dividend Yield(%)	0.78	0.97	0.39	0.12	0.08	0.05	0.07	0.11	0.09	0.04	0.05
EV/Net Sales(x)	0.83	0.57	0.84	1.78	2.3	2.99	1.94	1.47	2.36	3.14	3
EV/Core EBITDA(x)	7.44	5.58	8.53	17.73	23.13	21.96	13.6	9.63	13.12	16.2	15.12
Net Sales Growth(%)	19.84	22.83	23.2	33.42	21.42	24.47	14.79	8	28.74	59.76	-11.36
EBIT Growth(%)	53.75	13.8	7.83	50.72	25.05	87.54	17.19	-3.23	62	85.3	-13.06
PAT Growth(%)	118.01	28.09	-2.5	76.17	23.16	82.65	33.17	3.41	94.96	116.68	-16.84
EPS Growth(%)	118.03	28.09	-2.5	76.17	23.16	81.52	33.17	-16.98	94.96	116.67	-16.83
Debt/Equity(x)	1.55	1.27	1.21	1.26	1.52	1.47	1.3	0.9	0.32	0.23	0.9
Current Ratio(x)	1.14	1.15	1.09	1.15	1.12	1.18	1.21	1.14	1.51	1.72	1.61
Quick Ratio(x)	0.71	0.72	0.65	0.67	0.63	0.62	0.78	0.63	1.01	1.1	0.97
Interest Cover(x)	2.43	2.6	2.46	2.67	3.27	4.37	4.48	3.17	5.23	24.64	13.98
Total Debt/Mcap(x)	0.71	0.84	0.33	0.13	0.11	0.1	0.17	0.32	0.06	0.03	0.17

Gufic Biosciences Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	75.48	75.48	75	75	75	75	75	75	72.51	72.51
FII	1.69	1.51	1.38	0.06	0.16	0.72	0.7	0.72	0.47	0.12
DII	1.19	1.12	1.13	1.16	1.16	1.16	1.16	1.64	1.73	2.2
Public	21.64	21.89	22.49	23.78	23.69	23.12	23.14	22.64	25.29	25.18
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	7.32	7.32	7.27	7.27	7.27	7.27	7.27	7.27	7.27	7.27
FII	0.16	0.15	0.13	0.01	0.02	0.07	0.07	0.07	0.05	0.01
DII	0.12	0.11	0.11	0.11	0.11	0.11	0.11	0.16	0.17	0.22
Public	2.1	2.12	2.18	2.31	2.3	2.24	2.24	2.19	2.54	2.52
Others	0	0	0	0	0	0	0	0	0	0
Total	9.69	9.69	9.69	9.69	9.69	9.69	9.69	9.69	10.03	10.03

Pros

Company has delivered good profit growth of 37% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 33%

Cons

Debtor days have increased from 124.89 to 167.52days.
Stock is trading at 6.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Gufic Biosciences News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Gufic Biosciences

Add Watchlist

Gufic Biosciences Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Gufic Biosciences Share Price

Alert Data

Quarterly Price

Peer Comparison

Gufic Biosciences Quarterly Results

Gufic Biosciences Profit & Loss

Growth Rates

Gufic Biosciences Balance Sheet

Gufic Biosciences Cash Flow

Gufic Biosciences Ratios

Gufic Biosciences Shareholding Pattern

Gufic Biosciences News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!